Lucid Diagnostics Inc.
LUCDNasdaq
$0.95
↓ -6.4%Jul 17 close · end-of-day
Price
1Y↓ -12.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$133.1M
Enterprise Value
$133.1M
P/E
—
P/S
25.9
P/B
33.3
EV/EBITDA
—
PEG
—
FCF Yield
-35.1%
Dividend Yield
—
Revenue (TTM)
$5.1M
Net Income (TTM)
-$45.0M
Free Cash Flow (TTM)
-$46.7M
Gross Margin
—
Operating Margin
-959.6%
Net Margin
—
ROE
—
ROIC
-973.0%
Debt / Equity
—
Net Cash
—
Return 1Y
-16.7%
Company profile
Lucid Diagnostics Inc. focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux. The company was incorporated in 2018 and is based in New York, New York.
- CEO
- Lishan Aklog
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Headquarters
- New York
- Website
- luciddx.com
Management & directors
- Aklog LishanChief Executive Officer
- Gordon Michael AdamGeneral Counsel and Secretary
- Mcgrath Dennis MChief Financial Officer
- O'Neil ShaunPresident and COO
Roles derived from SEC Form 4 filings.
Earnings
LUCD Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.3M↑ +51.7%
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $500,000.00 | $377,000.00 | $2.4M | $4.3M | $4.7M |
| Gross profit | — | $500,000.00 | $377,000.00 | — | — | — |
| Operating income | -$8.3M | -$27.4M | -$56.3M | -$48.5M | -$46.1M | -$49.6M |
| Net income | -$8.3M | -$28.1M | -$56.2M | -$52.7M | -$45.5M | -$58.0M |
| Diluted EPS | — | — | -$1.55 | -$1.26 | -$1.05 | — |
| Operating cash flow | -$5.6M | -$17.7M | -$29.7M | -$32.8M | -$44.1M | -$46.5M |
| Free cash flow | — | -$18.5M | -$32.9M | — | -$44.4M | -$46.7M |
| Gross margin | — | 100.0% | 100.0% | — | — | — |
| Operating margin | — | -5483.8% | -14920.7% | -1996.8% | -1059.6% | -1054.8% |
| Net margin | — | -5615.6% | -14899.5% | -2169.1% | -1047.6% | -1232.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $976,000.00 | $1.2M | $1.2M | $828,000.00 | $1.2M | $1.2M | $1.5M | $1.3M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$11.2M | -$11.7M | -$12.4M | -$12.5M | -$11.4M | -$11.8M | -$14.0M | -$12.1M |
| Net income | -$11.0M | -$12.4M | -$11.5M | -$26.9M | -$4.4M | -$10.4M | -$16.3M | -$13.9M |
| Diluted EPS | -$0.23 | -$0.25 | -$0.17 | -$0.52 | -$0.08 | -$0.10 | — | — |
| Operating cash flow | -$11.5M | -$10.2M | -$9.9M | -$12.5M | -$10.5M | -$10.9M | -$12.6M | -$12.1M |
| Free cash flow | — | — | — | -$12.6M | — | — | — | -$12.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1146.7% | -997.8% | -1033.8% | -1508.1% | -978.8% | -971.0% | -931.5% | -964.5% |
| Net margin | -1127.6% | -1055.5% | -964.2% | -3249.8% | -381.7% | -858.5% | -1081.5% | -1107.4% |
Company news
May 15, 2026
May 14, 2026
- 67d agoLucid Diagnostics Inc (LUCD) Q1 2026 Earnings Call Highlights: Exceeding Test Targets and ...finance.yahoo.com
- 67d agoLucid Diagnostics Inc. Q1 2026 Earnings Call Summaryapp.moby.co
- 67d agoLUCD Q1 2026 Earnings Transcriptfool.com
- 67d agoLucid Diagnostics Q1 Earnings Call Highlightsmarketbeat.com
- 67d agoLucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Misses Revenue Estimatesfinance.yahoo.com
- 67d agoLucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Resultsfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-20 | Matheis Dennis | Buy | 245,000 | $1.00 | $245,269.50 | filing |
| 2026-02-20 | Aklog Lishan· Chief Executive Officer | Award | 2,170,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | Matheis Dennis | Award | 123,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | White Debra | Award | 123,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | Sparks Ronald M | Award | 123,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | SOKOLOV JACQUE J | Award | 123,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | PALUMBO JOHN R | Award | 123,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | Lapidus Stanley | Award | 123,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | Cox James L | Award | 123,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | MCGRATH DENNIS M· Chief Financial Officer | Award | 470,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | O'Neil Shaun· President and COO | Award | 620,000 | $0.00 | $0.00 | filing |
| 2026-02-20 | Gordon Michael Adam· General Counsel and Secretary | Award | 300,000 | $0.00 | $0.00 | filing |
| 2025-08-20 | Matheis Dennis | Buy | 100,000 | $1.02 | $101,840.00 | filing |
Latest 13 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.